Breast Cancer Update
Episodes
Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases
23 Dec 2025
Contributed by Lukas
Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago i...
Breast Cancer — Highlights from the 2025 ESMO Annual Meeting
08 Dec 2025
Contributed by Lukas
Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center...
Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
05 Dec 2025
Contributed by Lukas
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer...
Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
02 Dec 2025
Contributed by Lukas
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer...
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders, Part 2
29 Nov 2025
Contributed by Lukas
Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degrad...
Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
26 Nov 2025
Contributed by Lukas
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer...
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
20 Nov 2025
Contributed by Lukas
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degrader...
ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs
14 Nov 2025
Contributed by Lukas
Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, Cal...
Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
10 Nov 2025
Contributed by Lukas
Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their per...
ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
05 Nov 2025
Contributed by Lukas
Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with...
Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
27 Oct 2025
Contributed by Lukas
Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug ...
Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates
21 Oct 2025
Contributed by Lukas
Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the tr...
HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
14 Oct 2025
Contributed by Lukas
Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and ...
Breast Cancer — An ASCO 2025 Review
07 Oct 2025
Contributed by Lukas
Dr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently...
Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
29 Sep 2025
Contributed by Lukas
Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibod...
Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management
23 Sep 2025
Contributed by Lukas
Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple...
Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy
18 Sep 2025
Contributed by Lukas
Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast c...
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
16 Sep 2025
Contributed by Lukas
Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjug...
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management
15 Sep 2025
Contributed by Lukas
Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha f...
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1
09 Sep 2025
Contributed by Lukas
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson C...
Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
01 Sep 2025
Contributed by Lukas
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events ...
Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches
26 Aug 2025
Contributed by Lukas
Dr Sarah Sammons from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses cases and reviews the current management of brain metastases in...
Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
04 Aug 2025
Contributed by Lukas
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives...
Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management
29 Jul 2025
Contributed by Lukas
Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational ...
Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
04 Jul 2025
Contributed by Lukas
Dr Harold Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Joyce O’Shaughnessy and moderator Dr Hope S Rugo present data info...
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
23 Jun 2025
Contributed by Lukas
Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. ...
For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress
16 Jun 2025
Contributed by Lukas
Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clin...
Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and Advances
04 Jun 2025
Contributed by Lukas
Dr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summari...
5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
28 May 2025
Contributed by Lukas
Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of...
5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
19 May 2025
Contributed by Lukas
Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management ...
Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
06 May 2025
Contributed by Lukas
Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important e...
For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
26 Apr 2025
Contributed by Lukas
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conj...
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy
25 Apr 2025
Contributed by Lukas
Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer an...
HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit
21 Apr 2025
Contributed by Lukas
Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer. CME inform...
HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit
13 Apr 2025
Contributed by Lukas
Clinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer. CME information and s...
Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial Updates
08 Apr 2025
Contributed by Lukas
Dr Adrienne G Waks from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews recent trial updates and their significance for the management ...
Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L Moertel
28 Mar 2025
Contributed by Lukas
Dr Christopher L Moertel from the University of Minnesota in Minneapolis discusses the clinical presentation of and optimal management strategies for ...
HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Therapy
28 Mar 2025
Contributed by Lukas
Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes data presented at the recent 2024 San Antonio Breast Cance...
5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
22 Mar 2025
Contributed by Lukas
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management ...
Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical Management
12 Mar 2025
Contributed by Lukas
Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New Yo...
5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
04 Mar 2025
Contributed by Lukas
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-posit...
HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies
15 Feb 2025
Contributed by Lukas
Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Pro...
5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
10 Feb 2025
Contributed by Lukas
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic...
5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
31 Jan 2025
Contributed by Lukas
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic...
Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by Patients
24 Jan 2025
Contributed by Lukas
Dr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Il...
Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer
17 Jan 2025
Contributed by Lukas
For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in ...
Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3
10 Jan 2025
Contributed by Lukas
Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory Unive...
The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2
03 Jan 2025
Contributed by Lukas
Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, ...
HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1
23 Dec 2024
Contributed by Lukas
Dr Aditya Bardia, Professor Giuseppe Curigliano, Dr Hope Rugo and Dr Antonio C Wolff share their perspectives on the management of HER2-low breast can...
5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
16 Dec 2024
Contributed by Lukas
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic...
Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer
05 Dec 2024
Contributed by Lukas
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss rece...
5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
26 Nov 2024
Contributed by Lukas
Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-posi...
Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities
19 Nov 2024
Contributed by Lukas
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive...
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast Cancer
16 Nov 2024
Contributed by Lukas
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.
Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
01 Nov 2024
Contributed by Lukas
Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss i...
Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
25 Oct 2024
Contributed by Lukas
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor d...
Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors
18 Oct 2024
Contributed by Lukas
Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in N...
Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
25 Sep 2024
Contributed by Lukas
Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the ma...
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
06 Sep 2024
Contributed by Lukas
Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Mass...
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
29 Aug 2024
Contributed by Lukas
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer follow...
Oncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer
23 Aug 2024
Contributed by Lukas
Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of m...
Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
16 Aug 2024
Contributed by Lukas
Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-dr...
Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer
07 Aug 2024
Contributed by Lukas
Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with...
Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast Cancer
31 Jul 2024
Contributed by Lukas
Dr Kimberly H Allison from Stanford Cancer Institute in Stanford, California, discusses the optimal identification, pathologic reporting and treatment...
What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer
11 Jul 2024
Contributed by Lukas
Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center i...
Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer
13 Jun 2024
Contributed by Lukas
Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio M...
Oncology Today with Dr Neil Love: Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer
21 May 2024
Contributed by Lukas
Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive brea...
Virtual Case Library: Metastatic Triple-Negative Breast Cancer
09 May 2024
Contributed by Lukas
Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating j...
Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breast Cancer
26 Mar 2024
Contributed by Lukas
Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal...
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer
15 Mar 2024
Contributed by Lukas
Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, K...
Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer
11 Mar 2024
Contributed by Lukas
Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ...
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer
01 Feb 2024
Contributed by Lukas
Dr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Inst...
Implications of Recent Data Sets for the Current and Future Management of Breast Cancer
30 Nov 2023
Contributed by Lukas
Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discu...
Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
29 Sep 2023
Contributed by Lukas
Dr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Ket...
Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series
30 Aug 2023
Contributed by Lukas
Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, m...
Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor
24 Aug 2023
Contributed by Lukas
Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville...
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
09 Aug 2023
Contributed by Lukas
Dr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual me...
Oncology Today with Dr Neil Love: Special Edition — Current and Future Management of Breast Cancer
21 Jul 2023
Contributed by Lukas
Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky, moderated by Dr Neil Love.
Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part Series
16 Jun 2023
Contributed by Lukas
Featuring a discussion on the management of soft tissue sarcoma and related connective tissue disorders with Dr Brian Van Tine, moderated by Dr Neil L...
Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 3 of a 3-Part Series
27 Apr 2023
Contributed by Lukas
Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara A Hurvitz, moderated by Dr Neil Love.
Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 2 of a 3-Part Series
31 Mar 2023
Contributed by Lukas
Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara Tolaney, moderated by Dr Neil Love. ?
Recent Advances and Future Directions in Breast Cancer — With Dr Harold Burstein and Dr Virginia Kaklamani (Proceedings from a Symposium in Partnership with NCOA and SCOS)
17 Mar 2023
Contributed by Lukas
Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring...
Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer
10 Mar 2023
Contributed by Lukas
Featuring a discussion on the current role of ovarian suppression in the management of breast cancer with Drs Kathy Miller and Ann Partridge, moderate...
Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 1 of a 3-Part Series
24 Feb 2023
Contributed by Lukas
Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Komal Jhaveri, moderated by Dr Neil Love.
Oncology Today with Dr Neil Love: Special Edition — Management of ER-Positive Breast Cancer
31 Jan 2023
Contributed by Lukas
Featuring a discussion on ER-positive breast cancer with Drs Erica Mayer and Ruth O’Regan, moderated by Dr Neil Love.
Oncology Today with Dr Neil Love: HER2-Positive Metastatic Breast Cancer
26 Jan 2023
Contributed by Lukas
Featuring a discussion of recent advances in the treatment of HER2-positive metastatic breast cancer with Professor Giuseppe Curigliano, moderated by ...
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer
17 Jan 2023
Contributed by Lukas
Proceedings from our Year in Review webinar on the management of breast cancer. Featuring perspectives from Dr Joyce O’Shaughnessy and Prof Peter Sc...